Effect of recombinant human soluble thrombomodulin on clinical outcomes of patients with coagulopathy after hematopoietic stem cell transplantation

European Journal of Haematology

Volumn 91, Issue 5, 2013, Pages 442-447

  Ikezoe, Takayuki ^a   Takeuchi, Asako ^a   Chi, Sunggi ^a   Takaoka, Masato ^a   Anabuki, Kazuki ^a   Kim, Tsukie ^a   Sakai, Mizu ^a   Taniguchi, Ayuko ^a   Togitani, Kazuto ^a   Yokoyama, Akihito ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

Recombinant human soluble thrombomodulin; Sinusoidal obstructive syndrome; Transplantation associated microangiopathy

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III CONCENTRATE; CYCLOSPORIN A; DEFIBROTIDE; FIBRINOGEN; FLUDARABINE; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT THROMBOMODULIN; TACROLIMUS; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE CONCENTRATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LUNG INJURY; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTICOAGULANT THERAPY; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; BRAIN HEMORRHAGE; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTHROMBIN TIME; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; T CELL LEUKEMIA; THROMBOCYTE COUNT;

RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN; SINUSOIDAL OBSTRUCTIVE SYNDROME; TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY;

ADULT; AGED; ANTICOAGULANTS; ANTITHROMBIN III; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPARIN; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SOLUBILITY; SURVIVAL ANALYSIS; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 84885933700     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12188     Document Type: Article

References (18)

1. DeLeve LD, Ito Y, Bethea NW, McCuskey MK, Wang X, McCuskey RS. Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastrointest Liver Physiol 2003;284:G1045-52.
2. Choi CM, Schmaier AH, Snell MR, Lazarus HM. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 2009;69:183-98.
3. Suzuki K, Hayashi T, Nishioka J, Kosaka Y, Zushi M, Honda G, Yamamoto S. A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J Biol Chem 1989;264:4872-6.
4. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82:718-21.
5. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41.
6. Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010;45:783-5.
7. Sakai M, Ikezoe T, Bandobashi K, Togitani K, Yokoyama A. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010;45:803-5.
8. Ikezoe T, Takeuchi A, Taniguchi A, Togitani K, Yokoyama A. Recombinant human soluble thrombomodulin counteracts capillary leakage associated with engraftment syndrome. Bone Marrow Transplant 2011;46:616-8.
9. Ikezoe T, Yang J, Nishioka C, Honda G, Furihata M, Yokoyama A. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. Arterioscler Thromb Vasc Biol 2012;32:2259-70.
10. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005;115:1267-74.
11. Nomura S, Ozasa R, Nakanishi T, Fujita S, Miyaji M, Mori S, Yokoi T, Ito T, Ishii K. Can recombinant thrombomodulin play a preventive role for veno-occlusive disease after haematopoietic stem cell transplantation? Thromb Haemost 2011;105:1118-20.
12. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984;4:116-22.
13. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
14. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
15. Guglielmelli T, Bringhen S, Palumbo A. Update on the use of defibrotide. Expert Opin Biol Ther 2012;12:353-61.
16. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007;13:1349-58.
17. Corbacioglu S, Cesaro S, Faraci M, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haematopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012;379:1301-9.
18. Matsumoto T, Wada H, Nishiyama H, et al. Hemostatic abnormalities and changes following bone marrow transplantation. Clin Appl Thromb Hemost 2004;10:341-50.